Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV)
TRLV trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1754195/000175419526000019/0001754195-26-000019-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TRLV on NYSE |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001754195 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | -$122.2M |
| Operating income | $143.5M |
| Net margin | -10.3% |
| Operating margin | 12.1% |
| Revenue growth | -0.4% |
| Cash | $255.5M |
| Total assets | $2.7B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $326.7M cash; operating cash flow $60.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 170,631,619 (2026-10-30); 191,158,338 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, New York, New York, United States | PCAOB Form AP 2026-02-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $14.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $230.2M | $774K | $74.4M | $326.7M | $196.0M | $1.1B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $271.0M | -$406.1M | $53.1M | $325.4M | $195.8M | $1.1B | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $286.8M | $2.3M | $55.7M | $352.9M | $195.6M | $1.2B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $293.1M | -$43.6M | $59.2M | $255.5M | $136.7M | $1.2B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $288.2M | -$28.8M | $76.4M | $449.2M | $366.1M | $1.2B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $302.1M | -$16.1M | $86.1M | $392.6M | $365.7M | $1.2B | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $297.8M | -$33.8M | $51.1M | $328.5M | $365.3M | $1.2B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $301.1M | -$61.6M | $30.7M | $238.8M | $364.8M | $1.2B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-06-30 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-06-25 |
Source: SEC EDGAR submissions feed, 416 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.7% |
| 1 month | +7.8% |
| 3 months | +13.5% |
| Year to date | +25.4% |
| 1 year | +77.2% |
| From 52-week high | -16.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier